Results 201 to 210 of about 176,756 (350)

A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors

, 2017
Kurt W. Evans, Erkan Yuca, Argun Akçakanat, Stephen Scott, Natalia Paez Arango, Xiaofeng Zheng, Ken Chen, Coya Tapia, Emily Tarco, Agda Karina Eterovic, Dalliah M. Black, Jennifer K. Litton, Timothy A. Yap, Debu Tripathy, Gordon B. Mills, Funda Meric‐Bernstam   +15 more
openalex   +2 more sources

Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP Inhibition [PDF]

, 2018
Pingping Fang, Jill A. Madden, Lisa Neums, Ryan K. Moulder, M. Laird Forrest, Jeremy Chien   +5 more
openalex   +1 more source

FIGURE 1 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>

, 2023
Lisa Marie Fröhlich, Heike Niessner, Birgit Sauer, Sofie Kämereit, Eftychia Chatziioannou, Simon Riel, Tobias Sinnberg, Birgit Schittek   +7 more
openalex   +1 more source

Inhibition of HMGA2 Leads to Reduced Cell Proliferation and Increased Apoptosis in Human Embryonal Carcinoma Cell Lines

Andrology, EarlyView.
ABSTRACT Background The most prevalent solid tumors in young men are testicular germ cell tumors (TGCTs), and embryonal carcinoma is the most common subtype among non‐seminomatous germ cell tumors (NSGCTs). Despite the excellent cure rates of cisplatin‐based chemotherapy, resistance develops in 15%–30% of patients with metastatic cancer, which results ...
Marco De Martino, Matteo Lampitto, Alfredo Fusco, Marco Barchi, Francesco Esposito, Paolo Chieffi   +5 more
wiley   +1 more source

Poly(ADP-ribose) polymerase (PARP) inhibitors in cardiovascular, and cerebrovascular diseases: mechanisms, current trends and challenge for clinical translation. [PDF]

PeerJ
Fan J, Song Y.
europepmc   +1 more source

PARP enzymes and mono-ADP-ribosylation: advancing the connection from interferon-signalling to cancer biology [PDF]

Barbara Morone, Giovanna Grimaldi
openalex   +1 more source

Supplementary Table S3 from Targeting <i>MALAT1</i> Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate Cancer

, 2023
Anjali Yadav, Tanay Biswas, Ayush Praveen, Promit Ganguly, Ankita Bhattacharyya, Ayushi Verma, Dipak Datta, Bushra Ateeq   +7 more
openalex   +1 more source

Selective small molecule targeting of KDM4 as a therapeutic strategy to reduce proliferation of acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Summary Acute myeloid leukaemia (AML) is an aggressive disease with poor survival and high relapse rates. Coupled with the complex mutational burden observed, there is an unmet clinical need for more targeted therapies. Epigenetic therapies have shown promise both as monotherapy and in combination strategies and specifically histone lysine demethylase,
Laura Monaghan, Roderick P. Bunschoten, Joana Bittencourt‐Silvestre, Taeju Park, Susan Gannon, Petrisor Alin Pirvan, Alex Hoose, Helen Wheadon, Robert M. J. Liskamp, Xu Huang, Heather G. Jørgensen   +10 more
wiley   +1 more source

PARP‐1 activation causes mitochondrial dysfunction [PDF]

, 2002
Raymond A. Swanson, Weihai Ying, Conrad C. Alano, Y. Chen   +3 more
openalex   +1 more source

Malignant craniopharyngiomas: Institutional experience and literature review

Brain Pathology, EarlyView.
We report the second case of malignant craniopharyngioma with BAP1 and TP53 mutations. A literature review identified 44 cases of malignant craniopharyngiomas with a median overall survival of 6 months. Eighteen (41%) occurred in patients without any history of radiation, suggesting that mechanisms other than radiation have contributed to their ...
Thomas J. Auen, Isabella W. Zhang, Weiwei Zhang, Jordan M. Burr, Matthew L. Carda, James L. Wisecarver, Nicole Shonka, Jesse L. Cox, Sahara J. Cathcart, Allison Cushman‐Vokoun, Jie Chen   +10 more
wiley   +1 more source